Status and perspectives of neuroprotective therapies in glaucoma: the European Glaucoma Society White Paper.

Authors :: Tamm ER
Schmetterer L
Grehn F
Source :: Cell and tissue research [Cell Tissue Res] 2013 Aug; Vol. 353 (2), pp. 347-54. Date of Electronic Publication: 2013 May 28.
Publication Year :: 2013
Abstract: Glaucoma, a chronic progressive neuropathy and the most frequent cause of irreversible blindness worldwide, is commonly treated by medication or surgery aimed at lowering intraocular pressure. In view of the limited therapeutic options, the European Glaucoma Society (EGS) sponsored two Think Tank Meetings with the goal of assessing the current status and the overall perspectives for neuroprotective treatment strategies in glaucoma. The results of the meetings are summarized in this EGS White Paper.

Subjects :: Apoptosis
Biomarkers metabolism
Congresses as Topic
Disease Progression
Europe
Glaucoma diagnosis
Glaucoma pathology
Humans
Optics and Photonics
Research Report
Retinal Ganglion Cells pathology
Stem Cell Transplantation
Translational Research, Biomedical
Glaucoma drug therapy
Neuroprotective Agents therapeutic use
Societies, Medical

Full Text Access

Tools